Radium-223 dichloride (Xofigo®) for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease by Breuer, J. et al.
 Horizon Scanning 
in Oncology 
Radium-223 dichloride 
(Xofigo®) for the treatment 
of patients with castration-
resistant prostate cancer, 
symptomatic bone metastases 
and no known visceral 
metastatic disease 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DSD: Horizon Scanning in Oncology No. 44 
ISSN online 2076-5940 
 Horizon Scanning 
in Oncology 
Radium-223 dichloride 
(Xofigo®) for the treatment 
of patients with castration-
resistant prostate cancer, 
symptomatic bone metastases 
and no known visceral 
metastatic disease 
 
 
 
 
 
 
 
 
 
 
 
 
Vienna, March 2014 
 Institute for Health Technology Assessment 
Ludwig Boltzmann Gesellschaft in collaboration with the Italian Horizon Scanning Project, Dipartimento Farmaceutico, 
Azienda ULSS 20, Verona/Italy (IHSP) and the Agency for Health Technology Assessment in Poland (AOTM) 
 
Project leader: Dr. med. Anna Nachtnebel, MSc (LBI-HTA Vienna) 
Authors:  Mag. Johanna Breuer (LBI-HTA Vienna) 
 Dr. Roberta Joppi (IHSP) 
Dr. Chiara Poggiani (IHSP) 
Marta Polkowska, MSc Pharm (AOTM) 
External review: Prof. Dr. Christian Schwentner, FEBU 
Zentrum für Urogenitale Tumore, Universitätsklinik Tübingen 
 
 
 
 
 
 
DISCLAIMER 
This technology summary is based on information available at the time of research and on a limited literature search.  
It is not a definitive statement on safety, effectiveness or efficacy and cannot replace professional medical advice nor 
should it be used for commercial purposes. 
 
This product of collaboration with the Italian Horizon Scanning Project (IHSP) and the Agency for Health Technology 
Assessment in Poland (AOTM) is an offspring of the European network for Health Technology Assessment 
(EUnetHTA) project that was supported by a grant from the European Commission. The sole responsibility lies with 
the author(s), and the Commission is not responsible for any use that may be made of the information contained 
therein. 
 
 
 
CONTACT INFORMATION 
Publisher: 
Ludwig Boltzmann Gesellschaft GmbH 
Nußdorferstr. 64, 6 Stock, A-1090 Vienna 
http://www.lbg.ac.at/de/lbg/impressum 
Responsible for Contents: 
Ludwig Boltzmann Institut für Health Technology Assessment (LBI-HTA) 
Garnisongasse 7/20, A-1090 Vienna 
http://hta.lbg.ac.at/ 
Decision support documents of the LBI-HTA do not appear on a regular basis and serve to publicise  
the research results of the Ludwig Boltzmann Institute of Health Technology Assessment. 
Decision support documents of the LBI-HTA are only available to the public via the Internet at 
http://eprints.hta.lbg.ac.at. 
DSD: Horizon Scanning in Oncology No. 44 
ISSN-online: 2076-5940 
http://eprints.hta.lbg.ac.at/view/types/ 
© 2014 LBI-HTA – All rights reserved 
 LBI-HTA | 2014 3 
1 Drug description 
Generic/Brand name/ATC code:  
Radium-223 dichloride (formerly Alpharadin)/Xofigo
®
/V10XX03 
Developer/Company:  
Bayer HealthCare Pharmaceuticals Inc. 
Description:  
Radium-223 dichloride is a radiopharmaceutical composed of the dichloride 
salt of the alpha-emitting isotope radium-223, with antineoplastic activity. It 
targets bone tissue and accumulates in areas of high bone turnover by form-
ing a complex with hydroxyapatite, the inorganic calcium-containing con-
stituent of bone. Since bone metastases frequently demonstrate increased 
bone metabolism, radium-223 is taken up preferentially in areas of bone me-
tastases. Radium-223 is an alpha emitter and has thus a higher energy and a 
shorter ionisation path than existing beta-emitting radiopharmaceuticals. 
The physical half-life of radium-223 is 11.4 days [1-4]. 
 
Xofigo
®
 is available as a solution for injection (vials containing 6 ml of solu-
tion, each ml of solution contains 1,000 kBq radium Ra-223 dichloride). The 
dose regimen of Xofigo
®
 is 50 kBq (1.35 microcurie) per kg body weight, giv-
en at four-week intervals for six injections [3, 5]. 
 
 
2 Indication 
Xofigo
®
 is indicated for the treatment of patients with castration-resistant 
prostate cancer (CRPC), symptomatic bone metastases and no known vis-
ceral metastatic disease. 
 
 
3 Current regulatory status 
On 13 November 2013, the European Medicines Agency (EMA) licensed 
Xofigo
® 
(radium-223 dichloride) for the treatment of adults with CRPC, 
symptomatic bone metastases and no known visceral metastases [6]. 
The U.S. Food and Drug Administration (FDA) approved Xofigo
®
 (radium-
223 dichloride) for the treatment of patients with CRPC, symptomatic bone 
metastases and no known visceral metastatic disease on 15 May 2013 [5]. 
 
radium-223 dichloride is 
an alpha emitter with a 
half-life of 11.4 days 
 
given intravenously at 
four-week intervals for 
six injections 
indicated for CRPC, bone 
metastases, no known 
visceral metastatic 
disease 
EMA licensed Xofigo® in 
November 2013 
 
 
FDA licensed Xofigo® in 
May 2013 
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4 Burden of disease 
417,000 new cases of prostate cancer were diagnosed in Europe in 2012 [7]. In 
Austria, about 4,700 men were newly diagnosed with prostate cancer and 1,146 
died in 2011. Prostate cancer is therefore the most common type of cancer in 
Austrian men. Due to widespread prostate-specific antigen (PSA) testing, 
prostate cancer is mostly diagnosed at an early, asymptomatic stage of disease, 
resulting in 60% of patients being diagnosed before the tumour has spread [8]. 
From 2006 to 2010, the median age at diagnosis for cancer of the prostate was 
66 years [9]. 
Risk factors for developing prostate cancer include age, ethnicity, family his-
tory, diet and genetic factors such as mutations in BRCA1 and BRCA2 genes. 
Prognostic factors are age, extent of tumour, histologic grade of tumour and 
the PSA level [10, 11]. 
Staging is done by using the TNM system which provides information for 
choosing the initial therapy. Other factors which impact on the choice of ini-
tial therapy are life expectancy, comorbidities, therapeutic side effects and pa-
tients’ preferences. Besides the TNM system, the Gleason score is used to es-
tablish prognosis. This score is a histopathologic grading system that distin-
guishes between well and poorly differentiated prostate tissue [11]. 
Prognosis strongly depends on the stage at diagnosis. If the tumour is con-
fined to the prostate gland, a median survival of more than five years can be 
expected. Locally advanced forms of prostate cancer can rarely be cured, but 
median survival is still about five years. Patients with metastasised tumours 
have a median survival of one to three years [12]. 
Osteoblastic metastases to the skeleton are prevalent in most men with 
mCRPC causing pain, debility, and/or functional impairment leading to re-
duced quality of life. Bone destruction is an important factor in the aetiology 
of pain and other complications due to bone metastases. Measurement of bi-
ochemical bone markers such as alkaline phosphatase (ALP) can be a relia-
ble indicator for therapeutic response [13]. With disease progression visceral 
metastases may occur [14].  
 
 
5 Current treatment 
Androgen deprivation therapy (ADT) is generally the initial treatment for 
men with metastatic prostate cancer. Despite initial response rates of 80 to 
90%, nearly all men eventually develop progressive disease following ADT 
[15].  
If the PSA level rises despite castrate levels of testosterone (serum testos-
terone < 20 ng/dl) the cancer is called “castrate-resistant”, “hormone-
refractory” or “androgen-independent”. Therapeutic options for CRPC are: 
 Multiple and sequential secondary hormone therapies including 
withdrawal of ADT, antiandrogen therapy, oestrogens and cortico-
steroids [16]. 
prostate cancer  
most common cancer 
affecting men in Austria 
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TNM staging and the 
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prevalent with advanced 
disease 
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 Immunotherapy with sipuleucel-T indicated for minimally sympto-
matic/asymptomatic and chemotherapy-naive patients [12, 17]. 
 Arbiraterone acetate usually administered with prednisone and not 
only given in hormone-refractory patients but also in patients after 
docetaxel.  
 Docetaxel injection concentrate in combination with prednisone [12, 
18] is seen as the standard first-line treatment for mCRPC who are 
suitable candidates for chemotherapy because of its survival benefit 
[12, 19].  
However, many patients experience progression of disease after docetaxel or 
are not eligible for docetaxel therapy. Systemic therapeutic options then are:  
 Abiraterone acetate: a CYP17 inhibitor usually administered with 
prednisone 
 Cabazitaxel: a “second-generation” taxane in addition to prednisone  
 Enzalutamide: an oral androgen-signaling inhibitor  
 Mitoxantrone: an anthracenedione antineoplastic agent [12, 18, 20]. 
 
Besides these systemic therapies, palliative therapies (like external beam 
radiation therapy) may be used for treating bone pain that is limited to one 
or a limited number of sites. In men with extensive painful bone metastases 
and those with persistent or recurrent pain despite receiving radiation 
therapy to maximal normal tissue tolerance, treatment with multiple beta-
emitting radiopharmaceuticals or focused ultrasound is recommended [14, 
18, 21].  
Concerning specific bone-targeted therapies, i.e. therapies which are primar-
ily active in the bones and show no influence on visceral metastases, two 
groups may be distinguished: 
 Osteoclast-targeted therapies: azoledronic acid and denosumab 
 Bone-seeking radioisotopes: strontium-89 (beta emitter) and samar-
ium-153 (beta and gamma emitter). 
These therapies can also be given in an earlier stage of disease or additional-
ly to other agents and are administered to prevent skeletal events [20]. 
 
 
6 Evidence 
A literature search was conducted on the 12
th
 of December 2013 in four data-
bases (Medline, Embase, CRD, Cochrane Central). Search terms were “pros-
tate cancer”, “radium-223”, “xofigo” and “alpharadin”. Overall, 231 refer-
ences were identified through literature search. The manufacturer addi-
tionally submitted 14 posters, nine articles, four phase II and one phase III 
study. The phase II and III trials had already been identified through lit-
erature search. Eligible for inclusion were phase III trials (full text, ab-
stracts) and phase II studies published as full text but also other study de-
signs such as results from compassionate-use programmes or meta-analyses. 
After applying these inclusion criteria, one phase III trial [22] and four phase 
II trials [23-26] were included in this report. 
therapy options after 
disease progression on 
docetaxel 
painful bone metastases 
can be treated with 
radiation therapy, beta 
emitters or focused 
ultrasound 
two groups of bone-
targeted therapies 
literature search in four 
databases: 231 hits 
 
included: one phase III, 
four phase II trials 
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6.1 Efficacy and safety – phase III studies 
Table 1: Summary of efficacy 
Study title  
Alpha emitter radium-223 and survival in metastatic prostate cancer [3, 20, 22, 27] 
Study  
identifier 
NCT00699751, ALSYMPCA trial 
Design Double-blind, placebo-controlled trial, phase III, randomisation in a 2:1 ratio, 
international, multicentre (136 study centres in 19 countries) 
Duration  Enrolment: June 2008–February 2011 
Follow-up: 3 years 
Cut-off dates for analyses: 14 Oct 2010 (interim analysis) and 15 
July 2011 (updated analysis) 
Hypothesis Superiority 
90% to detect a hazard ratio of 0.76 for the risk of death in the radium-223 group 
compared with the placebo group, with a two-sided alpha significance level of 0.05. 
Funding Bayer HealthCare Pharmaceuticals Inc. 
Treatment 
groups 
 
Intervention 
(n=614) 
Six intravenous injections of radium-223 (at a dose of 50 kBq per 
kilogram of body weight); one injection administered every 4 
weeks plus best standard of care.  
Best standard of care includes e.g. local external beam 
radiotherapy, bisphosphonates, corticosteroids, antiandrogens, 
oestrogens, estramustine or ketoconazole [3] 
Control 
(n=307) 
Matched placebo (saline injections) plus best standard of care 
(as above) 
Endpoints 
and 
definitions 
Overall survival 
(primary outcome) 
OS Time from randomisation to the date of death, 
regardless of cause 
Time to first 
symptomatic 
skeletal event 
- First use of external-beam radiation therapy to relieve 
skeletal symptoms, new symptomatic pathologic 
vertebral or nonvertebral bone fractures, spinal cord 
compression, or tumour-related orthopaedic surgical 
intervention 
Time to increase in 
total ALP level 
- Increase of ≥25% from baseline at ≥12 weeks in 
patients with no decrease from baseline, or as an 
increase of ≥25% above the nadir, confirmed ≥3 weeks 
later, in patients with an initial decrease from baseline 
Total ALP response - Reduction of ≥30% from the baseline value, confirmed 
≥4 weeks later 
Time to increase in 
PSA level 
- Relative increase of ≥25% from the baseline level and 
an absolute increase of ≥2 ng per millilitre at ≥12 weeks 
in patients with no decrease in the PSA level from 
baseline, or a relative increase of ≥25% and an absolute 
increase of ≥2 ng per millilitre above the nadir, 
confirmed ≥3 weeks later, in patients with an initial 
decrease from baseline 
Normalisation of 
the total ALP level 
- Return to a value within the normal range at 12 weeks 
(confirmed by two consecutive measurements ≥2 
weeks apart) in patients with total alkaline 
phosphatase values above the upper limit of the 
normal range at baseline 
Quality of life QOL Increase in the score of ≥10 points on a scale of 0–156 
on the Functional Assessment of Cancer Therapy-
Prostate (FACT-P) instrument 
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Results and analysis 
Analysis  
description 
ITT 
A formal interim analysis was planned after 50% of the deaths (320 deaths). A 
stratified log-rank test was used as the primary analysis for survival. Other endpoints 
were tested at a two-sided significance level of 0.05. 
Analysis  
population 
Inclusion  Progressive CRPC with two or more bone metastases detected on 
skeletal scintigraphy and no known visceral metastases 
 Patients who received docetaxel, were not healthy enough or 
declined to receive it, or for whom it was not available 
 Serum testosterone level of 50 ng per decilitre or lower  
 Symptomatic disease with regular use of analgesic medication or 
treatment with external-beam radiation therapy required for 
cancer-related bone pain within the previous 12 weeks 
 Baseline PSA level of 5 ng per millilitre or higher with evidence 
of progressively increasing PSA values 
 ECOG performance-status score 0–2 
 Life expectancy of 6 months or longer 
 Adequate haematological, renal and liver function 
Exclusion  Chemotherapy within the previous 4 weeks or not recovered 
from Aes due to chemotherapy 
 Previous hemibody external radiotherapy, systemic radiotherapy 
with radioisotopes within the previous 24 weeks 
 Blood transfusion or use of erythropoietin-stimulating agents 
within the previous 4 weeks 
 Malignant lymphadenopathy (>3 cm in the short-axis diameter) 
 History of or presence of visceral metastases and imminent or 
established spinal cord compression 
Characteristics  Age – median (range): I 71 (49-90) vs C 71 (44-94) 
 ≥75 years, no of patients (%): I 171 (28) vs C 90 (29) 
 Total ALP, no of patients (%) 
<220 U/litre: I 348 (57) vs C 169 (55) 
≥220 U/litre: I 266 (43) vs C 138 (45) 
 Current use of bisphosphonates, no of patients (%) 
Yes: I 250 (41) vs C 124 (40) No: I 364 (59) vs 183 (60) 
 Any previous use of docetaxel, no of patients (%) 
Yes: I 352 (57) vs C 174 (57) No: I 262 (43) vs C 133 (43) 
 ECOG performance-status score 0/1/≥2, no of patients (%) 
I 165 (27) vs C 78 (25)/I 371 (60) vs C 187 (61)/I 77 (13) vs C 41 (13) 
 WHO ladder for cancer pain 1/2/3, no of patients (%) 
I 257 (42) vs C 137 (45)/I 151 (25) vs C 78 (25)/I 194 (32) vs C 90 (29) 
 Extent of disease, %: <6/6-20/>20 metastases/Superscan:  
I 16 vs C 12/I 43 vs C 48/I 32 vs C 30/I 9 vs C 10 
 External-beam radiation therapy within 12 weeks after 
screening, no of patients (%) 
Yes: I 99 (16) vs C 48 (16) No: I 515 (84) vs C 259 (84) 
 Median biochemical values (range) 
Haemoglobin – g/dl: I 12.2 (8.5–15.7) vs C 12.1 (8.5–16.4) 
Albumin – g/litre: I 40 (24–53) vs C 40 (23–50) 
Total ALP – U/litre: I 211 (32–6431) vs C 223 (29–4805) 
Lactate dehydrogenase – U/litre: I 315 (76–2171) vs C 336 (132–3856) 
Horizon Scanning in Oncology 
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PSA – µg/litre: I 146 (3.8–6026) vs C 173 (1.5–14500) 
Results 
(interim 
analysis) 
Treatment group Intervention 
Radium-223 
Control 
Placebo 
Number of subjects N=541 N=268 
Median OS, months 
95% CI 
14.0 
12.1–15.8 
11.2 
9.0–13.2 
Results 
(updated 
analysis) [3, 
27] 
*p –value 
<0.001 
 
 
 
 
 
 
 
 
 
 
 
 
 
Subgroups 
Overall treatment group Intervention 
Radium-223 
Control 
Placebo 
Number of subjects N=614 N=307 
Median OS, months 
95% CI 
14.9 
13.9–16.1 
11.3 
10.4–12.8 
Median time to first 
symptomatic skeletal 
event, months  
95% CI* 
15.6 
 
 
13.5–18.0 
9.8 
 
 
7.3–23.7 
Median time to increase in 
total ALP level, months 
95% CI* 
7.4 
 
NR 
3.8 
 
NR 
Median time to increase in 
PSA level, months 
95% CI* 
3.6 
 
NR 
3.4 
 
NR 
Median time to 
deterioration in FACT-P 
total score (QOL), months 
6.3 5.6 
Number of subjects N=497 N=211 
Patients with ≥30% 
reduction in total ALP 
response, no (%)* 
233 (47) 7 (3) 
Number of subjects N=321 N=140 
Patients with 
normalisation of total ALP 
level, no (%)* 
109 (34) 2 (1) 
   
Effect 
estimate per 
comparison 
Comparison groups  Intervention vs Control 
OS (interim analysis) HR 0.70 
95% CI 0.55–0.88 
P value <0.002 
OS (updated analysis) HR 0.70 
95% CI 0.58–0.83 
P value <0.001 
Median time to first 
symptomatic skeletal 
event 
HR 0.66 
95% CI 0.52–0.83 
P value <0.001 
Median time to increase in 
total ALP level 
HR 0.17 
95% CI 0.13–0.22 
P value <0.001 
Median time to increase in 
PSA level 
HR 0.64 
95% CI 0.54–0.77 
P value <0.001 
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Median time to 
deterioration in FACT-P 
total score (QOL) 
HR 0.75 
95% CI 0.59–0.94 
P value 0.015 
Subgroup 
analysis 
OS, patients with no/with 
previous docetaxel use  
HR 0.71/0.74 
95% CI 0.56–0.89/0.56–0.99 
P value NR 
OS, patients aged <65/65-
75/>75 
HR 0.49/0.73/0.82 
95% CI 0.29-0.81/0.51-1.03/0.53-1.27 
P value 0.005/0.072/0.381 
OS, patients with baseline 
ECOG PS 0 or 1/≥2 
HR 0.68/0.82 
95% CI 0.56–0.82/0.50–1.35 
P value NR 
OS, patients with <6/6–20 
metastases 
HR 0.95/0.71 
95% CI 0.46–1.95/0.54–0.92 
P value NR 
OS, patients with >20 
metastases/superscan 
HR 0.64/0.71 
95% CI 0.47–0.88/0.40–1.27 
P value NR 
Abbreviations: AEs = adverse events, ALP = alkaline phosphatase, C = control, cm = centimetre, CI = confidence interval, 
CRPC = castration-resistant prostate cancer, ECOG PS = Eastern Cooperative Oncology Group performance status, FACT-
P = Functional Assessment of Cancer Therapy-Prostate, g/dl = gram/decilitre, g/litre = gram/litre, HR = hazard ratio, I = 
intervention, ITT = intention to treat, kBq = kilobecquerel, no = number, ng = nanogram, nmol = nanomol, NR = not re-
ported, OS = overall survival, PSA = prostate-specific antigen, QOL = quality of life, U/litre = units/litre, WHO = World 
Health Organization 
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Table 2: Most frequent AEs (All Grades: >15%, Grade 3: >3%, Grade 4: >2%, Grade 5: >1% are displayed) 
NCT00699751 [20, 22] 
Grade (according  
to CTCAE version 3.0) Outcome, n (%) Radium-223 (n=600) Placebo (n=301) 
All Grades Anaemia 187 (31) 92 (31) 
Constipation 108 (18) 64 (21) 
Diarrhoea 151 (25) 45 (15) 
Nausea 213 (36) 104 (35) 
Vomiting 111 (18) 41 (14) 
Fatigue 154 (26) 77 (26) 
Weight loss 69 (12) 44 (15) 
Anorexia 102 (17) 55 (18) 
Bone pain 300 (50) 187 (62) 
Progression of malignant 
neoplasm 
77 (13) 44 (15) 
Grade 3 Anaemia 65 (11) 37 (12) 
Thrombocytopenia 20 (3) 5 (2) 
Fatigue 21 (4) 16 (5) 
Bone pain 120 (20) 74 (25) 
Pathologic fracture 13 (2) 8 (3) 
Spinal cord compression 14 (2) 16 (5) 
Grade 4 Anaemia 11 (2) 2 (1) 
Thrombocytopenia 18 (3) 1 (<1) 
Grade 5 Deterioration in general 
physical health 
5 (1) 2 (1) 
Pneumonia 4 (1) 0 
Progression of malignant 
neoplasm 
55 (9) 33 (11) 
Dyspnoea 1 (<1) 3 (1) 
Others Patients with serious AEs 281 (47) 181 (60) 
Patients with at least 1 
AE leading to treatment 
discontinuation 
93 (16) 57 (19) 
Therapy discontinuation 
because of AEs 
99 (16) 62 (21) 
Aes with an outcome of 
death during treatment 
period + 30 days 
16 (3) 14 (5) 
Aes with an outcome of 
death 3-year follow up 
44 (7) 36 (12) 
Abbreviations: AEs = adverse events, CTCAE = Common Terminology Criteria for Adverse Events, n = number of patients 
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In the ALSYMPCA trial (a randomised, double-blind, multicentre study) 
the efficacy and safety of radium-223 in patients with CRPC was investigat-
ed. Overall, 921 patients were randomly assigned in a 2:1 ratio to best sup-
portive care plus radium-223 (one dose every four weeks for six cycles) or 
best supportive care plus placebo. Best standard of care included e.g. local 
external beam radiotherapy, bisphosphonates, corticosteroids, antiandro-
gens, oestrogens, estramustine or ketoconazole [3]. Patients with confirmed 
CRCP were included who had either progressed on docetaxel chemotherapy 
or were not candidates for docetaxel chemotherapy. Additionally, patients 
were required to have two or more symptomatic bone metastases and no 
known visceral metastases. The median age of patients included was 71 
years. 28% of the patients in the treatment group and 29% in the placebo 
group were ≥ 75 years old. 526 (57%) of the patients had received prior 
docetaxel (radium-223 group: n = 352; placebo group: n = 174). The majori-
ty of the study population had a good ECOG performance status (0 or 1) and 
had 6–20 or more than 20 metastases. Besides best standard of care, concom-
itant therapies were blood transfusions and erythropoietin-stimulating 
agents. Cytotoxic agents, systemic radioisotopes, hemibody, or other investi-
gational drugs were prohibited and prompted treatment discontinuation [3].  
OS, the primary endpoint of the trial, was 14.9 months in the radium-223 
group compared with 11.3 months in the placebo group (HR 0.70, 95% CI 
0.58–0.83, p<0.001) in the updated analysis. The interim analysis on OS 
showed 14.0 months in the intervention group and 11.2 months in the con-
trol group (HR 0.70, 95% CI 0.55–0.88, p<0.002). The interim analysis was 
evaluated by an independent data and safety monitoring committee. Based 
on this evaluation which showed a survival advantage of radium-223 and an 
acceptable safety profile, the committee recommended early discontinuation 
of the trial and crossover from placebo to radium-223. The survival benefit 
was consistent across the patient subgroups (patients with previous/no pre-
vious docetaxel use, ECOG performance status, number of metastases). Sec-
ondary outcomes like the time to first symptomatic skeletal event was longer 
in the treatment group (HR 0.66, 95% CI 0.52–0.83, p<0.001). The time to 
increase in total ALP level was 7.4 months in the radium-223 group and 3.8 
months in the placebo group (HR 0.17 95% CI 0.13–0.22) and the time to in-
crease in PSA level was extended for patients treated with radium-223 by 0.2 
months (HR 0.64, 95% CI 0.54–0.77, p<0.001). In terms of quality of life, 
the median time to deterioration in the FACT-P total score was 6.3 months 
for patients treated with radium-223 compared with 5.6 months in patients 
with placebo (HR 0.75, 95% CI 0.59–0.94, p=0.015) [27]. 
Bone pain (50%), nausea (36%) and anaemia (31%) were the most common 
treatment-related AEs of all grades with radium-223. In the control group, 
62% of the patients experienced bone pain, 35% nausea and 31% anaemia as 
AEs of all grades. 281 patients (47%) treated with radium-223 and 181 pa-
tients (60%) of the control group had serious AEs. Therapy was discontin-
ued because of AEs in 99 patients (16%) receiving radium-223 and in 62 pa-
tients (21%) in the control group respectively. Deaths were less common in 
the treatment group compared to the placebo group (55% vs. 63%) [20, 22]. 
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6.2 Efficacy and safety – further studies 
Four phase II studies [23-26] in patients with CRPC and bone metastases 
were identified. 
A multicentre, randomised, double-blind phase II trial [23] evaluated the ef-
ficacy and safety of three different doses of radium-223 chloride in 122 pa-
tients with CRPC and bone metastases. Patients received either three injec-
tions at six-week intervals at doses of 25 kBq/kg (n=41), 50 kBq/kg (n=39) 
or 80 kBq/kg (n=42). The primary endpoint was PSA response (≥50% de-
crease from baseline) to the three dose regimens. ≥ 50% PSA declines were 
shown for no patient (0%) in the 25 kBq/kg-dose group, two patients (6%) in 
the 50 kBq/kg-dose group, and five patients (13%) in the 80 kBq/kg-dose 
group (p=0.0297). Bone ALP differed between the 25 kBq/kg and the 50 
kBq/kg-dose groups, favouring the 50 kBq/kg group. Differences in terms of 
bone ALP response were also evident between the 25 kBq/kg and the 80 
kBq/kg-dose group (favouring the 80 kBq/kg-dose group) but not between 
the 50 kBq/kg and the 80 kBq/kg-dose groups. 122 (92%) patients reported 
one or more AEs. The most common treatment-related AEs (≥10%) across 
all dose groups were diarrhoea (21%), nausea (16%), and anaemia (14%). 
For all dose groups the safety profile showed no dose response (except an in-
crease of gastrointestinal AEs). Dose-dependent improvements in confirmed 
50% PSA declines between the 25 and 80-kBq/kg and the 25 and 50-kBq/kg 
cohorts were shown and no increase in toxicity occurred [20, 23]. 
Another multicentre, randomised phase II study [24] evaluated the dose-
response relationship and pain-relieving effect of radium-223 in 100 patients 
with CRPC and painful bone metastases. Patients received a single intrave-
nous dose of 5, 25, 50 or 100 kBq/kg radium-223. The primary endpoint was 
pain index. A significant dose response for pain index was evident at week 
two (p=0.035). At week eight there were 40%, 63%, 56% and 71% pain re-
sponders (reduced pain and stable analgesic consumption) in the 5, 25, 50 
and 100 kBq/kg groups respectively. At least one AE was reported by 97% of 
the patients. The most frequent haematological AEs were anaemia (11%) 
and haemoglobin decrease (15%), with no differences between dose groups. 
A multicentre, randomised, double-blind, placebo-controlled phase II trial 
[25] was conducted in 64 CPRC patients with bone pain requiring external-
beam radiotherapy. Patients in the treatment group (n=33) were given 4 in-
jections of radium-223 at 50 kBq/kg every four weeks or placebo (n=31). 
Primary endpoints were change in bone-ALP concentration and time to 
skeletal-related events. The median change in bone ALP was -65.6% (95% 
CI -69.5 to -57.7) compared to 9.3% (95% CI 3.8 to 60.9) in the placebo 
group (p<0.0001). Median time to first skeletal-related event was 14 weeks 
in the treatment group and 11 weeks in the placebo group (p=0.257). Medi-
an OS for patients treated with radium-223 was 65.3 weeks (95% CI 48.7 to 
∞) and 46.4 weeks (95% CI 32.1 to 77.4) for the control group (p=0.066). 12 
serious AEs were reported in 8 patients receiving radium-223 compared with 
19 serious AEs in patients receiving placebo. 
At two-year survival follow-up (results of continuation of the previous study 
[25]), 10 patients (30%) of the radium-223 group were alive compared with 
four patients (13%) in the control group. The most frequent cause of death 
for both groups was progression of disease. Treatment-related AEs or long-
term haematological toxicity during the follow-up were not reported [26]. 
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7 Estimated costs 
Xofigo
®
 is available as a solution for injection (vials containing 6 ml of solu-
tion, each ml of solution contains 1000 kBq radium Ra-223 dichloride). The 
six ml vial costs € 4,600 in Austria (price for social health insurance) [28].  
Cost information for Xofigo
®
 in the US varies between around $69,000 [29] 
and $82,800 [30] for the complete course of therapy (six injections given at 
four-week intervals). 
 
 
8 Ongoing research 
At http://clinicaltrials.gov/ and https://www.clinicaltrialsregister.eu/ctr-
search/ two ongoing phase III studies investigating radium-223 in patients 
with CRPC were found. 
 NCT01618370: A prospective, interventional, open-label, multicentre 
trial for the use of radium-223 in CRPC patients diagnosed with bone 
metastasis, aiming to collect additional short-term and long-term 
safety data. The estimated study completion date is April 2015. 
 NCT01810770: A single-arm, international, prospective, open-label, 
multicentre study of radium-223 dichloride in the treatment of pa-
tients with CRPC with bone metastasis, aiming to evaluate the safety 
and efficacy of multiple doses of Ra-223 dichloride in an Asian popu-
lation. The estimated study completion date is April 2018. 
 
Several other phase I and phase II studies are currently conducted in pa-
tients with CRPC but also in patients with sarcoma (NCT01833520) and in 
breast-cancer patients with a bone-dominant disease (NCT01070485). No 
ongoing trials were identified examining radium-223 in combination or 
compared with enzalutamide, cabazitaxel, abiraterone acetate or mitoxan-
trone. A study investigating radium-223 in combination with docetaxel in 
patients with CRPC is currently recruiting participants (NCT01106352). 
The estimated study completion date is October 2014. 
 
 
9 Commentary 
In November 2013, the EMA licensed Xofigo
® 
(radium-223 dichloride) for 
the treatment of adults with CRPC, symptomatic bone metastases and no 
known visceral metastases [6, 31]. The FDA had already licensed Xofigo
® 
(radium-223 dichloride) for the same indication in May 2013 [5]. 
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A phase III study [22] examined the efficacy and safety of radium-223 in pa-
tients with CRPC having two or more symptomatic bone metastases. 921 pa-
tients were randomly assigned to radium-223 (one dose every four weeks for 
six cycles) plus best supportive care or to placebo plus best supportive care. 
Best supportive care included e.g. local external beam radiotherapy, 
bisphosphonates, corticosteroids, antiandrogens, oestrogens, estramustine or 
ketoconazole. For patients treated with radium-223, OS was extended by 3.6 
months (14.9 versus 11.3 months, HR 0.70, 95% CI 0.58–0.83). Subgroup 
analysis demonstrated that OS improvement was consistent across sub-
groups, but patients with increased age (>75 years) and prior docetaxel 
showed a less pronounced benefit [20]. The secondary endpoints time to 
skeletal event, time to alkaline phosphatase progression and time to PSA 
progression favoured treatment with radium-223. Quality of life (measured 
by EQ-5D, FACT-P) showed a decline in both arms, but to a lesser extent in 
the radium-223 arm. Mean differences in FACT-P scores were statistically 
significant in only one instance (at 16-week follow-up), but a higher propor-
tion of patients had a response in this score (24.6% versus 16.1%) [20]. 
In terms of safety, the most frequent AEs of all grades were bone pain, nau-
sea, anaemia and diarrhoea in both groups. However, in the radium-223 
group fewer people died (55% vs. 63%), fewer deaths were due to AEs (19% 
vs. 28%), fewer non-fatal serious AEs (44% vs. 57%) occurred, less people 
discontinued due to AEs (16% versus 19%) and overall fewer grade 3 and 4 
AEs (59% versus 65%) were observed [20]. 
Even though other radioisotopes are available for the palliation of bone 
pain, radium-223 is the first alpha emitter. Differences concerning radium-
223 are, first of all, that already available therapies such as strontium-89 or 
samarium-153 were licensed due to their effect on bone pain and not, like 
radium-223, based on their effect on OS. Secondly, since alpha emitters have 
a shorter ionisation path than beta and gamma emitters, radiation-related 
toxicities to adjacent tissue are expected to be rarer [4].  
Despite radium-223’s impact on OS [22], questions of where to precisely in-
corporate the radioisotope in the therapeutic pathway cannot be fully an-
swered yet. Lack of significant toxicity and its gains in OS [20, 32] may qual-
ify this compound for combination therapy even for patients with visceral 
disease [32]. No ultimate statement can be made because in the phase III 
study, radium-223 was not examined in combination with other systemic 
therapies, including enzalutamide, arbiraterone acetate or docetaxel [32, 33], 
but radium-223 is currently investigated in combination with docetaxel 
(NCT01106352). The results are eagerly awaited, also due to the potential 
for additive myelosuppression [12]. Moreover, when selecting appropriate 
therapies, different modes of administration of available treatment regimens 
have to be taken into account and may determine patients’ preferences. En-
zalutamide and abiraterone acetate are taken orally, while cabazitaxel and 
radium-223 are administered intravenously. 
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Furthermore, the radiopharmaceutical may also be used for earlier stages of 
disease, for example, instead of sipuleucel-T indicated for minimally symp-
tomatic/asymptomatic and chemotherapy-naive patients, but administration 
of chemotherapy after radium-223 and its influence on safety have not been 
evaluated yet either [32]. Earlier use raises the question of long-term safety 
primarily concerning the risk of secondary malignancies. Epidemiology 
studies have demonstrated an increased risk of bone sarcoma and possible 
association with other secondary malignancies and hereditary defects. The 
expected latency period for bone sarcomas and other secondary malignan-
cies exceeds the duration of follow-up in the ALSYMPCA trial (which was 
three years) [20]. The risk for secondary malignancies needs to be examined 
in post-marketing observations. With Radium-223 there is also a potential 
risk due to radiation or contamination from body fluids for medical staff and 
family members [20, 34-36]. 
Also, the optimal dose of radium-223 is still a topic under discussion. As the 
improved level of efficacy with a comparable level of safety shows, the re-
sults of the phase II trial [22] suggest that the optimal dose of radium-223 
could be higher than the 50 kBq/kg used in the phase III study [20]. Chang-
es in dosage directly affect costs, and cost comparisons can only be made 
conditionally because of varying lengths of therapy cycles. When radium-
223 is administered as an alternative treatment path to enzalutamide, cost 
estimates differ. Costs for enzalutamide are estimated at $59,600 (assuming 
a median of eight cycles) [35] and for radium-223 between $69,000 [28] and 
$82,800 [29] in a six-month course of treatment. Cabazitaxel (six cycles) 
costs about $50,000, and the costs for abiraterone acetate are about $47,000 
(eight-month course of treatment) [36]. However, when radium-223 will be 
administered in addition to other treatment regimens, either concurrently or 
sequentially, the costs for treating patients with prostate cancer will increase 
even further.  
As bone metastases occur in many solid tumours, radium-223 may also be 
used in the future for other patient populations and in new areas of applica-
tion [37]. Currently, radium-223 is investigated in patients with sarcoma 
and in breast-cancer patients with a bone-dominant disease [37]. 
To summarise, radium-223 leads to increased OS in patients with CPRC and 
symptomatic bone metastases compared with patients getting best standard 
of care. A topic under discussion is whether placebo is a valid comparator 
considering the need to compare radium-223 with other already licensed 
agents. Moreover, optimal dosing of radium-223 and its implementation in 
the therapeutic pathway have yet to be examined. 
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